Items in AFP with MESH term: Evidence-Based Medicine

Pages: Previous 1 ... 16 17 18 19 20 21 22 23 24 25 26 Next

Are Beta Blockers Effective First-line Treatments for Hypertension? - Cochrane for Clinicians

Effectiveness of Insulin Sensitizing Drugs for Polycystic Ovary Syndrome - Cochrane for Clinicians

Best Alternatives to Statins for Treating Hyperlipidemia - FPIN's Clinical Inquiries

Prevention, Recognition, and Management of Serotonin Syndrome - Article

ABSTRACT: Serotonin syndrome is a potentially life-threatening condition caused by excessive serotonergic activity in the nervous system. It is characterized by mental status changes, autonomic instability, and neuromuscular hyperactivity. Most reported cases of serotonin syndrome are in patients using multiple serotonergic drugs or who have had considerable exposure to a single serotonin-augmenting drug. Diagnosis is made using the Hunter Serotonin Toxicity Criteria, which require the presence of one of the following classical features or groups of features: spontaneous clonus; inducible clonus with agitation or diaphoresis; ocular clonus with agitation or diaphoresis; tremor and hyperreflexia; or hypertonia, temperature above 100.4°?F (38°?C), and ocular or inducible clonus. Most cases of serotonin syndrome are mild and may be treated by withdrawal of the offending agent and supportive care. Benzodiazepines may be used to treat agitation and tremor. Cyproheptadine may be used as an antidote. Patients with moderate or severe cases of serotonin syndrome require hospitalization. Critically ill patients may require neuromuscular paralysis, sedation, and intubation. If serotonin syndrome is recognized and complications are managed appropriately, the prognosis is favorable.

For Hyperlipidemia, Go Where the Evidence Takes You: Give a Statin and Nothing Else - Editorials

Opioids for Osteoarthritis of the Knee or Hip - Cochrane for Clinicians

Prescribing Evidence: The Effectiveness and Safety of New Drugs - Editorials

Neonatal Resuscitation: An Update - Article

ABSTRACT: Appropriate resuscitation must be available for each of the more than 4 million infants born annually in the United States. Ninety percent of infants transition safely, and it is up to the physician to assess risk factors, identify the nearly 10 percent of infants who need resuscitation, and respond appropriately. A team or persons trained in neonatal resuscitation should be promptly available to provide resuscitation. The Neonatal Resuscitation Program, which was initiated in 1987 to identify infants at risk of needing resuscitation and provide high-quality resuscitation, underwent major updates in 2006 and 2010. Among the most important changes are to not intervene with endotracheal suctioning in vigorous infants born through meconium-stained amniotic fluid (although endotracheal suctioning may be appropriate in nonvigorous infants); to provide positive pressure ventilation with one of three devices when necessary; to begin resuscitation of term infants using room air or blended oxygen; and to have a pulse oximeter readily available in the delivery room. The updated guidelines also provide indications for chest compressions and for the use of intravenous epinephrine, which is the preferred route of administration, and recommend not to use sodium bicarbonate or naloxone during resuscitation. Other recommendations include confirming endotracheal tube placement using an exhaled carbon dioxide detector; using less than 100 percent oxygen and adequate thermal support to resuscitate preterm infants; and using therapeutic hypothermia for infants born at 36 weeks’ gestation or later with moderate to severe hypoxic-ischemic encephalopathy.

Opioid Therapy for Chronic Noncancer Pain - Cochrane for Clinicians

ICD-9 Update 2011: Approaching the Change to ICD-10 - Feature

Pages: Previous 1 ... 16 17 18 19 20 21 22 23 24 25 26 Next

Information From Industry